Phase 1 Study of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-08-06
Target enrollment:
Participant gender:
Summary
This is a phase 1, multicenter, open-label study to evaluate the safety, tolerability, PK,
PD, immunogenicity and preliminary efficacy of Y101D in patients with metastatic or locally
advanced solid tumors.